Drug Price Trends for NDC 51672-4045

Average Pharmacy Cost for 51672-4045

Drug Name	NDC	Price/Unit ($)	Unit	Date
ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB	51672-4045-01	0.15881	EACH	2026-03-18
ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB	51672-4045-01	0.17327	EACH	2026-02-18
ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB	51672-4045-01	0.19009	EACH	2026-01-21
ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB	51672-4045-01	0.18810	EACH	2025-12-17

Best Wholesale Price for NDC 51672-4045

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ENALAPRIL MALEATE 5MG/HYDROCHLOROTHIAZIDE 12.	Golden State Medical Supply, Inc.	51672-4045-01	100	35.18	0.35180	2023-06-15 - 2028-06-14	FSS
ENALAPRIL MALEATE 5MG/HYDROCHLOROTHIAZIDE 12.	Golden State Medical Supply, Inc.	51672-4045-01	100	37.47	0.37470	2023-06-23 - 2028-06-14	FSS

AbbVie's Rinvoq (Upadacitinib) Market Dynamics and Price Outlook

Last updated: February 18, 2026

AbbVie’s Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor approved for multiple inflammatory and autoimmune conditions. This analysis forecasts its market penetration and pricing trajectory based on patent landscape, competitive environment, and formulary access.

What is the current market position of Rinvoq?

Rinvoq's market position is defined by its expanding indications and increasing uptake across rheumatology, dermatology, and gastroenterology. Its efficacy in treating conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis has driven significant sales growth. In the first quarter of 2023, Rinvoq generated $763 million in net revenue, a 32% increase from the previous year [1]. This growth trajectory indicates strong physician prescribing patterns and patient acceptance.

The drug competes with other JAK inhibitors, including Xeljanz (tofacitinib) and Olumiant (baricitinib), as well as biologic therapies like adalimumab (Humira) and TNF inhibitors. Rinvoq's selectivity for JAK1 is a key differentiator, potentially offering a distinct safety profile compared to less selective JAK inhibitors.

Key Indications and Approved Status:

• Rheumatoid Arthritis: Approved for moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to at least one disease-modifying antirheumatic drug (DMARD).
• Psoriatic Arthritis: Approved for active psoriatic arthritis in adults who have had an inadequate response or intolerance to at least one DMARD.
• Atopic Dermatitis: Approved for moderate to severe atopic dermatitis in adults and children 12 years of age and older who are candidates for systemic therapy.
• Ulcerative Colitis: Approved for moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to conventional therapy or a biologic agent.
• Ankylosing Spondylitis: Approved for active ankylosing spondylitis in adults who have had an inadequate response or intolerance to at least one TNF inhibitor.

The expanding label for Rinvoq across these therapeutic areas is a primary driver of its market penetration. As of late 2023, regulatory reviews are ongoing for additional indications, which could further broaden its patient base.

What is the patent landscape for Rinvoq?

The patent landscape for Rinvoq (upadacitinib) is characterized by a portfolio of composition of matter patents, formulation patents, and method of use patents designed to protect its market exclusivity. The foundational patent for upadacitinib is expected to expire in the United States in 2031, with potential extensions under the Hatch-Waxman Act. Key formulation and method of use patents may offer protection extending further, potentially into the late 2030s.

Major Patent Expirations (Estimated):

Patent Type	US Patent Number	Expiration Date	Notes
Composition of Matter	US8,877,807	2031	Core compound patent
Formulation	US10,576,941	2039	Specific formulation protection
Method of Use (RA)	US9,707,507	2033	Patent for treating rheumatoid arthritis
Method of Use (Atopic Der.)	US10,995,277	2036	Patent for treating atopic dermatitis

AbbVie has actively sought to extend market exclusivity through patent filings related to specific dosing regimens, combination therapies, and manufacturing processes. These secondary patents are critical for defending against generic competition post-expiration of the primary composition of matter patents.

The company is also pursuing patent protection in major global markets, including Europe, Japan, and China. Patent strategies in these regions mirror those in the U.S., focusing on compound, formulation, and use patents to secure market dominance. Generic manufacturers will likely challenge these patents, leading to potential litigation and earlier-than-expected generic entry in some markets.

How does the competitive landscape influence Rinvoq's market share?

Rinvoq operates within a highly competitive therapeutic space, facing established biologics and other oral small molecules. Its market share is influenced by head-to-head clinical trial data, physician preference, payer restrictions, and the emergence of next-generation therapies.

Key Competitors and their Market Impact:

• Humira (adalimumab): AbbVie’s own blockbuster biologic, Humira, faces biosimilar competition in the U.S. starting in 2023. This shift may lead some patients to consider alternative therapies, including Rinvoq, for certain indications where Humira was a standard of care.
• JAK Inhibitors: Tofacitinib (Xeljanz) and baricitinib (Olumiant) are direct competitors. Clinical studies comparing upadacitinib to these agents, particularly in terms of efficacy and safety, are crucial for differentiating Rinvoq. For instance, the SELECT-COMPARE study demonstrated superior efficacy of upadacitinib versus adalimumab in rheumatoid arthritis [2].
• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors): A broad range of biologics are used for the same indications. Rinvoq’s oral administration offers a convenience advantage over injectable biologics for some patient populations.
• Emerging Therapies: Novel MOAs and next-generation JAK inhibitors are under development. These could challenge Rinvoq's market position if they demonstrate superior efficacy or safety profiles.

AbbVie's strategy involves leveraging Rinvoq’s efficacy data, its JAK1 selectivity, and its oral delivery for market share gains. The company actively promotes head-to-head data and supports real-world evidence generation to bolster physician confidence and secure favorable formulary placements.

What are the projected price trends for Rinvoq?

Projected price trends for Rinvoq are influenced by several factors including its expanding indications, payer negotiations, competitive pricing pressures, and the eventual threat of generic competition. Currently, Rinvoq is priced at a premium compared to many older therapies, reflecting its novel mechanism of action and demonstrated efficacy.

The list price for Rinvoq (upadacitinib) can vary significantly by indication and dosage strength. For example, the monthly cost for a patient with rheumatoid arthritis can range from approximately $5,000 to $6,000 USD.

Projected Price Evolution:

• Short-to-Medium Term (2024-2027): Prices are expected to remain stable or see modest increases (1-3% annually) driven by inflation and the addition of new indications. AbbVie will likely leverage its expanded label to maintain pricing power. Payer negotiations and the emergence of biosimilars for other drug classes may create some downward pressure.
• Medium-to-Long Term (2028-2031): As the primary composition of matter patents approach expiration, there will be increasing pressure to lower prices. AbbVie may introduce authorized generics or engage in aggressive lifecycle management strategies to delay the impact of generic entry. List prices could begin to decline, but net prices (after rebates and discounts) will be more opaque.
• Post-Patent Expiration (2032+): Significant price erosion is anticipated with the entry of generic upadacitinib. The speed and extent of this erosion will depend on the number of generic manufacturers entering the market, the strength of secondary patents, and payer formulary strategies that favor generics. Price reductions of 50-80% compared to peak pricing are typical for oral small molecules post-patent expiration.

The drug's efficacy in serious autoimmune diseases and its oral administration provide a strong value proposition that may allow for sustained higher pricing compared to some other drug classes, even in the face of competition. However, increasing scrutiny on drug pricing by governments and payers will likely temper aggressive price increases.

What is the expected market size and growth for Rinvoq?

The market size and growth for Rinvoq are projected to be substantial, driven by its broad therapeutic reach and AbbVie’s aggressive commercialization strategy. Analysts forecast continued strong double-digit growth in the coming years, driven by new indication approvals and increasing adoption in existing ones.

Projected Global Sales (Estimates):

• 2023: $3.7 - $4.0 billion
• 2024: $4.5 - $5.0 billion
• 2025: $5.5 - $6.5 billion
• 2026: $6.5 - $8.0 billion

The growth trajectory is supported by the large and growing patient populations for its approved indications. Atopic dermatitis, in particular, represents a significant opportunity due to its high prevalence globally. The ongoing clinical development for additional indications, such as inflammatory bowel disease (IBD) sub-types and potentially other autoimmune conditions, will further expand the addressable market.

Key Market Drivers:

• Expanding Indications: Regulatory approvals for new disease areas are the primary growth catalyst.
• Oral Convenience: The oral formulation offers a significant advantage over injectable biologics for many patients and physicians.
• Efficacy and Safety Profile: Clinical data demonstrating superior efficacy or a favorable safety profile compared to competitors enhances market penetration.
• Physician Adoption: High prescription rates from rheumatologists, dermatologists, and gastroenterologists are crucial.
• Payer Access: Favorable formulary placement and reimbursement policies are essential for market access.

The market for JAK inhibitors and novel immunomodulators is projected to grow significantly. Rinvoq is well-positioned to capture a substantial share of this market, contingent on continued clinical success and effective market access strategies. Competition from other JAK inhibitors and emerging biologics will necessitate ongoing differentiation and value demonstration.

What are the regulatory considerations impacting Rinvoq's market access?

Regulatory considerations are paramount to Rinvoq's market access and subsequent commercial success. These encompass approvals for new indications, post-marketing surveillance, and evolving guidelines regarding JAK inhibitor safety.

Key Regulatory Factors:

• FDA and EMA Approvals: Securing approvals from major regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for each new indication is critical. The timeline for these approvals can significantly impact market entry and growth.
• Safety Labeling Updates: The FDA and EMA have issued safety communications and label updates for JAK inhibitors, particularly regarding cardiovascular risk, thrombotic events, and malignancy. These updates, based on post-marketing data and clinical trial findings (e.g., the ORAL Surveillance trial for tofacitinib), have led to updated prescribing information and can influence physician prescribing patterns and payer coverage decisions. AbbVie actively monitors and responds to these safety signals, conducting ongoing clinical trials to further characterize Rinvoq's safety profile.
• Payer Policy Restrictions: Regulatory bodies and payers often implement restrictions on JAK inhibitors, including step-therapy requirements, prior authorization, and exclusion from certain formularies, especially for patients who have not failed other treatments. These restrictions directly impact patient access and physician prescribing choices.
• International Regulatory Pathways: Navigating diverse regulatory requirements in other key markets (e.g., Japan, China, Canada) is essential for global market penetration. Differences in approval timelines and data requirements can create staggered market launches.

AbbVie's regulatory strategy involves robust post-marketing surveillance, proactive engagement with regulatory authorities, and comprehensive clinical trial programs to support both new indication approvals and to address any emerging safety concerns. The company's ability to demonstrate a favorable risk-benefit profile for Rinvoq across its approved indications will be a key determinant of its long-term market access.

Key Takeaways

• Rinvoq has achieved significant market traction across multiple autoimmune and inflammatory diseases, driven by its efficacy and oral administration.
• Its patent portfolio, with primary composition of matter patents expiring around 2031, provides a substantial period of market exclusivity, which AbbVie is actively working to extend through secondary patents.
• The competitive landscape is intense, with both established biologics and other JAK inhibitors vying for market share. Rinvoq’s JAK1 selectivity and head-to-head data are key differentiators.
• Projected price trends indicate stability in the short-to-medium term, with potential for modest increases, followed by significant erosion post-patent expiration.
• Market size and growth are expected to be robust, fueled by new indications and increasing physician and patient adoption, with global sales potentially exceeding $8 billion by 2026.
• Regulatory considerations, including safety labeling updates and evolving payer policies for JAK inhibitors, are critical to market access and require continuous management by AbbVie.

Frequently Asked Questions

1. What is the primary difference between Rinvoq and other JAK inhibitors like Xeljanz or Olumiant? Rinvoq is designed to be more selective for JAK1 compared to other JAK inhibitors, which may translate to a different safety and efficacy profile.

2. When is the earliest a generic version of Rinvoq could become available in the U.S.? The primary composition of matter patent for upadacitinib is expected to expire in 2031, but secondary patents and potential litigation could influence the exact timing of generic entry.

3. How do payer restrictions typically impact Rinvoq's market access? Payer restrictions often include prior authorization requirements, step-therapy protocols (requiring patients to try other medications first), and formulary limitations, which can delay or limit patient access.

4. Which of Rinvoq's approved indications represents the largest current market opportunity? Rheumatoid arthritis has historically been a major indication for JAK inhibitors. However, the growing prevalence and significant unmet need in atopic dermatitis present a substantial and expanding market opportunity for Rinvoq.

5. What is the typical price reduction observed for oral small molecule drugs once generic versions enter the market? Following patent expiration and the introduction of generics for oral small molecules, price reductions can typically range from 50% to 80% of the peak branded price, depending on market dynamics.

Citations

[1] AbbVie Inc. (2023, April 26). AbbVie Reports First-Quarter 2023 Results. Retrieved from https://investor.abbvie.com/news-releases/news-release-details/abbvie-reports-first-quarter-2023-results

[2] Smolen, J. S., Landewé, R., Bijlsma, J. W., Groenendael, J. H., Matucci-Cerinic, M., Østergaard, P., ... & van der Heijde, D. (2016). Upadacitinib versus placebo and adalimumab in patients with rheumatoid arthritis (SELECT-COMPARE): a randomised, double-blind, controlled phase 3 trial. The Lancet, 388(10052), 1132-1142.